A Phase 1, Open-label, Fixed-sequence Design Study To Assess The Effect Of Multiple Dose Administration Of Pf-06751979 On The Single Dose Pharmacokinetics Of Oral Midazolam In Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 28 Jul 2017
Price : $35 *
At a glance
- Drugs PF 6751979 (Primary) ; Midazolam
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Pfizer
- 24 Jul 2017 Status changed from recruiting to completed.
- 18 May 2017 Planned End Date changed from 27 Jun 2017 to 1 Jul 2017.
- 18 May 2017 Planned primary completion date changed from 27 Jun 2017 to 1 Jul 2017.